Journal article

Current and emerging therapies to combat persistent intracellular pathogens

Philip Arandjelovic, Marcel Doerflinger, Marc Pellegrini

Current Opinion in Pharmacology | ELSEVIER SCI LTD | Published : 2019


Intracellular pathogens such as HIV, hepatitis B virus, and Mycobacterium tuberculosis are responsible for millions of deaths worldwide and represent major obstacles to global health. Current treatment options have improved patient outcomes and extended life-expectancy in many countries; however, challenges such as latency, drug-resistance, and inflammatory pathology have necessitated advancements in curative strategies which go beyond the traditional antimicrobial focus. This review highlights recent advances in host-directed therapies to eradicate intracellular pathogens or augment the endogenous immune response by targeting host cell pathways. The 'kick and kill' strategy for HIV latency,..

View full abstract


Awarded by National Health and Medical Research Council Australia

Funding Acknowledgements

M.P. receives research support from: The National Health and Medical Research Council Australia (Grants 1107425 and 1045549); The Sylvia and Charles Viertel Senior Medical Research Fellowship; The Victorian State Government Operational Infrastructure Support and the Independent Research Institutes Infrastructure Support Scheme of the Australian Government National Health and Medical Research Council. M.D. receives research support from the CASS Foundation.